Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 140 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Cancer With Bone Metastasis Clear all
Active, not recruiting Phase 2 Interventional

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

NCT03821792
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

NCT00090363
View directory record Official record
Conditions
Prostate Cancer
Interventions
ZD4054 15 mg, Placebo, ZD4054 10 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Tucson, Arizona • Los Angeles, California • Gainsville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jul 23, 2026, 4:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

NCT01050504
View directory record Official record
Conditions
Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Recurrent Bladder Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

NCT01992016
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Ranolazine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

NCT00080678
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Docetaxel, Imatinib Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Jul 23, 2026, 4:19 PM EDT
Completed No phase listed Observational

Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy

NCT01516866
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
3
States / cities
Bethesda, Maryland • New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jul 23, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

NCT03442556
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jul 23, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

NCT00019695
View directory record Official record
Conditions
Stage IV Prostate Cancer, Bone Metastases, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
alendronate sodium, ketoconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

NCT00558272
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Bone Neoplasms
Interventions
AZD0530, Zoledronic Acid
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Pleasant Hill, California • Sacramento, California • Middlebury, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

NCT00003162
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer, Pain, Prostate Cancer
Interventions
pain therapy, radiation therapy
Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
234
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

NCT02099864
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Enzalutamide
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 4:19 PM EDT
Active, not recruiting Not applicable Interventional

Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer

NCT03085043
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Magnetic Resonance Whole Body Diffusion-Weighted Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

NCT01106352
View directory record Official record
Conditions
Bone Metastases, Castration-Resistant Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

NCT01074138
View directory record Official record
Conditions
Bone-Metastatic, Castration-Resistant Prostate Cancer
Interventions
KX2-391
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

NCT03406858
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab
Biological · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
19 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Study of SU11248 in Men With Advanced Prostate Cancer

NCT00299741
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sunitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

NCT01505868
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
Interventions
Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Not applicable Interventional

Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer

NCT00003903
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
management of therapy complications
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2013 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

NCT00038194
View directory record Official record
Conditions
Prostate Cancer
Interventions
imatinib mesylate, docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03204812
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Durvalumab, Tremelimumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 23, 2026, 4:19 PM EDT
Terminated Phase 1 Interventional Results available

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

NCT02995330
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bone marrow transplantation, Cytoxan, testosterone cypionate
Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jul 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

NCT00936975
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Fluorine F 18 Sodium Fluoride
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Durham, North Carolina • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Jul 23, 2026, 4:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

NCT03217747
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Refractory Malignant Solid Neoplasm, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Avelumab, Ivuxolimab, Radiation Therapy, Utomilumab
Drug · Biological · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 4:19 PM EDT